Does Anthem (Elevance Health) Cover Ozempic?

How Anthem (Elevance Health) Classifies Ozempic on Its Formulary

Anthem places Ozempic (semaglutide injection, 0.5 mg, 1 mg, or 2 mg) on its non-preferred specialty brand tier across the majority of its commercial PPO and HMO formularies. This tier designation, typically Tier 4 or Tier 5, carries higher cost-sharing than preferred brand GLP-1 receptor agonists such as Trulicity (dulaglutide), which Anthem lists on a lower preferred brand tier in many plan documents.

Formulary placement matters because it determines both cost and access. A non-preferred tier means Anthem will cover Ozempic, but only after the prescriber demonstrates that preferred alternatives were inadequate or not tolerated. The Endocrine Society's 2022 guidelines recommend GLP-1 receptor agonists as second-line agents for type 2 diabetes in patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, a clinical rationale that strengthens PA requests. Anthem's formulary updates occur quarterly, so tier placement can shift. Members should verify their specific plan's drug list through the Anthem member portal or by calling the number on their insurance card. Employer-sponsored plans and individual marketplace plans under the Anthem/Elevance umbrella may use different formulary versions, and self-funded employer groups can customize coverage rules entirely.

Ozempic's cardiovascular benefit profile, demonstrated in the SUSTAIN-6 trial (N=3,297), where semaglutide reduced major adverse cardiovascular events by 26% versus placebo (HR 0.74; 95% CI 0.58-0.95) [1], provides clinical use when requesting non-preferred brand coverage. Prescribers who cite this data in PA submissions tend to receive faster approvals.

Prior Authorization Requirements for Ozempic on Anthem Plans

Anthem requires prior authorization for Ozempic on nearly all commercial plan types. The PA process involves moderate administrative burden. Expect the review to take 5 to 10 business days for a standard request, or 24 to 72 hours for an expedited (urgent) request.

To approve PA, Anthem's clinical criteria generally require documentation of the following: a confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x), a recent HbA1c value (typically 7.0% or above despite current therapy), evidence that metformin was tried for at least 90 days at a maximally tolerated dose (or a documented contraindication such as eGFR <30 mL/min/1.73m²), and failure of or intolerance to at least one preferred-tier GLP-1 receptor agonist, usually Trulicity.

The prescriber submits the PA request electronically through Anthem's provider portal or via fax. Including lab results, medication history, and a brief clinical rationale in the initial submission reduces back-and-forth. The American Diabetes Association Standards of Care (2024) recommend GLP-1 receptor agonists for patients with type 2 diabetes who have or are at high risk for atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Citing these guidelines in the PA letter adds clinical weight.

One common pitfall: submitting a PA without documenting the specific reason a preferred agent failed. "Patient prefers Ozempic" is not sufficient. Instead, document adverse effects (e.g., injection site reactions with dulaglutide), inadequate glycemic response (HbA1c reduction <0.5% after 6 months), or a clinical contraindication.

Step Therapy: What Anthem Requires Before Approving Ozempic

Anthem enforces step therapy for Ozempic across most commercial formularies. Step therapy, sometimes called "fail first," requires patients to try and fail one or more lower-cost medications before the insurer will authorize coverage of a higher-tier drug.

For Ozempic, the typical Anthem step therapy sequence works like this. Step one: metformin at a dose of 1,500 to 2,000 mg daily for at least 90 days. Step two: a preferred-tier GLP-1 receptor agonist (usually Trulicity/dulaglutide) or, in some plan designs, an SGLT2 inhibitor such as Jardiance (empagliflozin) or Farxiga (dapagliflozin). Step three: Ozempic becomes available for coverage once steps one and two are documented as clinically unsuccessful or contraindicated.

Patients who switched from another insurer to Anthem and already have claims history showing prior metformin and dulaglutide use can request a step therapy override. Anthem accepts pharmacy claims data from the previous insurer as evidence, but the prescriber must explicitly request the override and attach the prior claims or medical records.

The SUSTAIN-7 trial (N=1,201) compared semaglutide directly against dulaglutide and found that semaglutide 0.5 mg reduced HbA1c by 1.5% versus 1.1% with dulaglutide 0.75 mg, while semaglutide 1 mg reduced HbA1c by 1.8% versus 1.4% with dulaglutide 1.5 mg (P<0.0001 for both comparisons) [2]. This head-to-head data provides strong clinical justification for switching from dulaglutide to semaglutide when glycemic targets are not met.

Some Anthem plans also accept documented intolerance rather than treatment failure. Gastrointestinal side effects (nausea, vomiting, diarrhea) affecting adherence to a preferred-tier agent qualify as intolerance. Document the specific adverse event, its severity, and its impact on the patient's ability to continue therapy.

Does Anthem Cover Ozempic for Weight Loss?

Short answer: no, for the vast majority of Anthem commercial plans. Ozempic is FDA-approved only for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease [3]. Its use for weight management without a type 2 diabetes diagnosis is considered off-label, and Anthem's standard policy excludes off-label weight loss indications for Ozempic.

Patients seeking GLP-1 receptor agonist therapy specifically for weight loss should ask about Wegovy (semaglutide 2.4 mg), which carries an FDA-approved indication for chronic weight management in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity. Anthem's coverage for Wegovy is a separate policy with its own PA criteria, and availability varies significantly by plan. Many employer-sponsored Anthem plans exclude anti-obesity medications entirely, while some marketplace plans include limited coverage.

The distinction between diabetes management and weight loss is not just semantic for Anthem. If a prescriber submits a PA for Ozempic with a primary diagnosis of obesity (E66.x) rather than type 2 diabetes (E11.x), the claim will almost certainly be denied. Even if the patient has both conditions, the PA documentation should lead with the diabetes diagnosis and HbA1c values. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease without diabetes [4], but this evidence supports the Wegovy indication, not an off-label Ozempic claim through Anthem.

Out-of-Pocket Costs and How to Lower Them

Without insurance, Ozempic's wholesale acquisition cost is approximately $935.77 per month for a single pen at maintenance dosing. With Anthem coverage after PA approval, members typically pay $150 to $300 per month in copay or coinsurance, depending on their plan's specialty tier cost-sharing structure. High-deductible health plans may require the member to pay the full negotiated rate until the deductible is met.

Three strategies can reduce these costs significantly.

Novo Nordisk Savings Card. Commercially insured patients (including those on Anthem plans) may be eligible for the manufacturer's savings offer, which can reduce the copay to as little as $25 per fill for up to 24 months. The savings card cannot be used with Medicare, Medicaid, or other government-funded programs. Patients should confirm eligibility at the Novo Nordisk patient assistance website and present the card at the pharmacy alongside their Anthem insurance card.

Anthem's Specialty Pharmacy Network. Anthem often requires Ozempic to be filled through a preferred specialty pharmacy (such as CarelonRx, Anthem's affiliated specialty pharmacy). Using a non-preferred pharmacy may result in higher cost-sharing or a coverage denial. Confirm the required pharmacy channel before the first fill.

Copay Accumulator Programs. Some Anthem plans use copay accumulator adjustment programs, which prevent manufacturer savings card payments from counting toward the member's deductible or out-of-pocket maximum. If the plan uses an accumulator, the patient may face a cost cliff mid-year when the savings card benefit is exhausted but the deductible remains unmet. Members should call Anthem to confirm whether their plan uses a copay accumulator before relying on the savings card as a long-term cost strategy.

A 2023 IQVIA analysis estimated that 79% of commercially insured patients receiving GLP-1 receptor agonists used some form of manufacturer copay support [5]. The financial dynamics of GLP-1 access are shifting rapidly as payers renegotiate rebate contracts with Novo Nordisk and Eli Lilly.

How to Appeal an Anthem Denial for Ozempic

An Ozempic denial from Anthem is not the end of the process. Anthem members have the right to file an internal appeal, and if that fails, an external review through their state's Independent Review Organization (IRO).

Step 1: Review the denial letter. Anthem is required to provide a written explanation of the denial reason, including the specific clinical criteria that were not met. Common denial reasons include insufficient documentation of step therapy failure, HbA1c not meeting the threshold, or missing lab work.

Step 2: File an internal appeal within 180 days. The prescriber should submit a detailed letter of medical necessity addressing each denial reason directly. Include updated lab results, a medication history timeline, and any relevant clinical guideline citations. Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Access to the full range of glucose-lowering therapies, including GLP-1 receptor agonists, is essential for individualized diabetes care" [6]. Quoting this type of expert position adds authority to the appeal.

Step 3: Request an expedited appeal if clinically urgent. If the patient's glycemic control is deteriorating (HbA1c rising, hypoglycemia events on current regimen, or progression of diabetic complications), Anthem must process an expedited appeal within 72 hours.

Step 4: External review. If the internal appeal is denied, members can request an external review through their state's IRO. The IRO is an independent panel of physicians who review the case without input from Anthem. According to CMS data on external review outcomes, external reviews overturn insurer denials in approximately 40-60% of cases for specialty medications when the appeal is supported by guideline-concordant documentation.

The entire process from initial denial to external review resolution typically takes 60 to 90 days. Patients should continue their current diabetes regimen during this period and explore the manufacturer savings card or patient assistance programs as a bridge if cost is a barrier.

Clinical Evidence Supporting Ozempic Coverage Requests

Strong clinical documentation is the single most effective tool for securing Anthem coverage. Three categories of evidence carry the most weight in PA and appeal submissions.

Glycemic efficacy data. The SUSTAIN clinical trial program established semaglutide's glucose-lowering profile across multiple comparator studies. In SUSTAIN-7, semaglutide 1 mg reduced HbA1c by 1.8 percentage points compared to 1.4 points with dulaglutide 1.5 mg (the highest approved dose of the preferred-tier alternative) over 40 weeks [2]. This 0.4-point difference is clinically meaningful. The ADA Standards of Care define an HbA1c reduction of ≥0.3% as a clinically significant treatment difference.

Cardiovascular outcomes. SUSTAIN-6 showed a 26% reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke with semaglutide versus placebo in patients with type 2 diabetes and high cardiovascular risk [1]. For patients with established ASCVD or multiple risk factors, this evidence supports Ozempic over agents without proven cardiovascular benefit.

Weight reduction as a secondary endpoint. In SUSTAIN-7, semaglutide 1 mg produced 6.5 kg mean weight loss versus 3.0 kg with dulaglutide 1.5 mg [2]. While weight loss alone does not justify Anthem coverage for Ozempic, the metabolic benefit of weight reduction in a patient with type 2 diabetes and obesity strengthens the overall clinical narrative.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "The evidence base for semaglutide in type 2 diabetes is among the most strong of any glucose-lowering agent introduced in the past decade" [7]. Including expert commentary of this nature in appeal letters contextualizes the clinical data for non-specialist reviewers.

Anthem Marketplace vs. Employer-Sponsored Plan Differences

Coverage for Ozempic varies between Anthem's individual marketplace (ACA exchange) plans and employer-sponsored group plans. Marketplace plans follow a standardized formulary within each metal tier (Bronze, Silver, Gold, Platinum), and Ozempic's tier placement is consistent within the same state and metal level. Employer-sponsored plans, especially self-funded arrangements, can customize formulary tiers, PA criteria, and step therapy requirements.

Self-funded employers using Anthem as a third-party administrator may exclude GLP-1 receptor agonists entirely, restrict them to specific clinical scenarios, or place them on a lower tier with reduced cost-sharing. There is no way to determine coverage without checking the specific plan's Summary of Benefits and Coverage (SBC) and formulary document.

Anthem's Medicare Advantage plans cover Ozempic under Part D for the type 2 diabetes indication with PA, but the manufacturer savings card is not available for Medicare beneficiaries. The FDA's approved labeling for Ozempic specifies the type 2 diabetes indication, which is the only indication covered under Part D. Medicare Advantage members facing high Part D costs may qualify for Novo Nordisk's Patient Assistance Program (PAP), which provides free medication to qualifying low-income patients.

Patients enrolled in Medicaid managed care plans administered by Anthem subsidiaries should check their state's Medicaid preferred drug list, which operates independently from Anthem's commercial formulary. Medicaid PDLs often prefer different GLP-1 agents based on state-level supplemental rebate agreements with manufacturers.